Aptamer Sciences Inc Logo

Aptamer Sciences Inc

Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.

291650 | KO

Overview

Corporate Details

ISIN(s):
KR7291650000
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로228번길 15 3동 301호(삼평동, 판교세븐벤처밸리1), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative aptamer-based technologies for therapeutics and diagnostics. The company leverages its proprietary integrated platforms to address unmet medical needs, primarily in oncology. Its therapeutic pipeline is centered on the ApDC™ (Aptamer-Drug Conjugate) platform, with lead candidate AST-201 advancing to clinical trials for treating GPC3-positive solid tumors like liver cancer. In the diagnostics segment, the company has developed and commercialized the AptoDetect™ platform, which includes AptoDetect™-Lung, an aptamer-based diagnostic kit for assessing lung cancer risk. Aptamer Sciences focuses on advancing its pipeline and forming strategic partnerships to commercialize its novel aptamer technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 84.4 KB
2025-09-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 104.9 KB
2025-09-09 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 39.4 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 40.2 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 51.0 KB
2025-09-09 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 5.9 KB
2025-09-09 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 77.9 KB
2025-09-08 00:00
M&A Activity
경영권변경등에관한계약체결
Korean 15.1 KB
2025-08-20 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 10.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 891.5 KB
2025-07-03 00:00
Regulatory News Service
풍문또는보도에대한해명
Korean 4.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 745.9 KB
2025-04-07 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 10.2 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.5 KB

Automate Your Workflow. Get a real-time feed of all Aptamer Sciences Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptamer Sciences Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptamer Sciences Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.